Bio News
Sanofi’s second-quarter sales totaled €11.5 billion, 8% above market expectations. Second-quarter sales of Dupixent rose 38% to €5.2 billion, and Sanofi raised its 2030 target to €25 billion. Despite the earnings report, Sanofi’s shares fell 7% that day.
BIOBOOK TEAM
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
